Document:

exv10w2

 

Exhibit 10.2

ECHO THERAPEUTICS, INC.

ORIGINAL ISSUE DISCOUNT SENIOR SECURED NOTE

THE OUTSTANDING PRINCIPAL AMOUNT OF THIS ORIGINAL ISSUE DISCOUNT SENIOR SECURED NOTE (THIS “NOTE”)
MAY BE LESS THAN THE PRINCIPAL AMOUNT SHOWN BELOW BECAUSE (I) THE PRINCIPAL AMOUNT OF THIS NOTE
WILL ACCRETE IN VALUE FROM THE DATE HEREOF, AND (II) THIS NOTE DOES NOT REQUIRE PHYSICAL SURRENDER
HEREOF IN ORDER TO EFFECT A PARTIAL PAYMENT HEREOF.

	 	 	 
	Issue Date: March, 24, 2008

	 	$                    

     FOR VALUE RECEIVED, ECHO THERAPEUTICS, INC., a Minnesota corporation (the “Company”), hereby
promises to pay to the order of )                    , or its permitted successors or assigns (the
“Holder”), the sum of                                          ($                    ) in same day funds, on or before March
24, 2009 (the “Maturity Date”).

     Except as permitted or required under Sections 3 and 4, the Company shall not have the right
to prepay any principal of this Note.

     The Company has issued this Note pursuant to a Securities Purchase and Loan Agreement, dated
as of March 24, 2008 (as amended, restated, supplemented or otherwise modified from time to time,
the “Securities Purchase Agreement”), between the Company and the Holder.

     The Company’s obligations under this Note, including, without limitation, its obligation to
make payments of principal hereon, are guaranteed by the Company’s subsidiaries and secured by the
assets and properties of the Company and the Company’s subsidiaries.

     The following terms shall apply to this Note:

1. DEFINITIONS.

     (a) Defined Terms. When used herein, the terms below shall have the respective
meanings indicated:

          “Acceleration Notice” has the meaning set forth in Section 3 of this Note.

          “Change of Control” means the existence, occurrence, public announcement or entering into an
agreement contemplating of any of the following: (a) the sale, conveyance or disposition of all or
substantially all of the assets of the Company to any Person, (b) the sale, conveyance or
disposition of all or substantially all of the assets of any Company Subsidiary to a

 

Person other than the Company or another Company Subsidiary that is a party to the Security
Documents; (c) the effectuation of a transaction or series of transactions in which more than fifty
percent (50%) of the equity or voting power of the Company is disposed of; (d) the effectuation of
a transaction or series of transactions in which any of the equity or voting power of any Company
Subsidiary is disposed to a Person other than the Company or another Company Subsidiary that is a
party to the Security Documents; (e) the consolidation, merger or other business combination of the
Company with or into any other entity, immediately following which the prior stockholders of the
Company fail to own, directly or indirectly, at least fifty percent (50%) of the surviving entity;
(f) the consolidation, merger or other business combination of any Company Subsidiary with or into
any other entity other than the Company or another Company Subsidiary that is a party to the
Security Documents; (g) a transaction or series of transactions in which any Person or group (other
than pursuant to an agreement between current affiliates of the Company) acquires more than fifty
percent (50%) of the equity or voting power of the Company; (h) a transaction or series of
transactions in which any Person or group (other than the Company or a Company Subsidiary that is a
party to the Security Documents) acquires any of the voting equity of a Company Subsidiary; and (i)
the Continuing Directors do not at any time constitute at least a majority of the Board of
Directors of the Company; provided that for purposes of clarity, any migratory merger effected
solely for the purpose of changing the jurisdiction of incorporation of the Company shall not
constitute a Change of Control.

          “Continuing Director” means, at any date, a member of the Board of Directors (i) who was a
member of such board on the Execution Date or (ii) who was nominated or elected by at least a
majority of the directors who were Continuing Directors at the time of such nomination or election
or whose election to the Board of Directors was recommended or endorsed by at least a majority of
the directors who were Continuing Directors at the time of such nomination or election or such
lesser number comprising a majority of a nominating committee if authority for such nominations or
elections has been delegated to a nominating committee whose authority and composition have been
approved by at least a majority of the directors who were Continuing Directors at the time such
committee was formed.

          “Default Interest Rate” means the lower of eighteen (18%) per annum and the maximum rate
permitted by applicable Governmental Requirements.

          “Event of Default” means the occurrence of any of the following events:

          (i) a Liquidation Event occurs or is publicly announced;

          (ii) the Company fails to make any payment on this Note as and when due, and such
payment remains unpaid for two (2) Business Days following such due date;

          (iii) other than a breach described in clause (ii) above, the Company or any Company
Subsidiary breaches or provides notice of its intent to breach any material agreement,
covenant, term or condition of this Note or any other Transaction Document (including,
without limitation, a Registration Default (as defined in the Registration Rights
Agreement)); and such breach continues beyond any applicable cure period (or if there is no

2

 

cure period, for a period of five (5) Business Days following written notice thereof
from the Holder);

          (iv) any representation or warranty made by the Company or any Company Subsidiary in
any of the Transaction Documents was inaccurate or misleading in any material respect as of
the date such representation or warranty was made (or deemed to have been made); or

          (v) a default occurs or is declared, or any amounts are accelerated, under or with
respect to any instrument that evidences Debt of the Company or any Company Subsidiary in a
principal amount exceeding $25,000.

          “Issue Date” means the date of this Note as set forth on the first page of this Note.

          “Liquidation Event” means where (i) the Company or any Company Subsidiary shall make a general
assignment for the benefit of creditors or consent to the appointment of a receiver, liquidator,
custodian, or similar official of all or substantially all of its properties, or any such official
is placed in control of such properties, or the Company or any Company Subsidiary shall commence
any action or proceeding or take advantage of or file under any federal or state insolvency
statute, including, without limitation, the United States Bankruptcy Code, seeking to have an order
for relief entered with respect to it or seeking adjudication as a bankrupt or insolvent, or
seeking reorganization, arrangement, adjustment, liquidation, dissolution, administration, a
voluntary arrangement, or other relief with respect to it or its debts; or (ii) there shall be
commenced against the Company or any Company Subsidiary any action or proceeding of the nature
referred to in clause (i) above or seeking issuance of a warrant of attachment, execution,
distraint, or similar process against all or any substantial part of its property, which results in
the entry of an order for relief which remains undismissed, undischarged or unbonded for a period
of sixty (60) days; or (iii) there is initiated the dissolution or other winding up of the Company
or any material Company Subsidiary, whether voluntary or involuntary and whether or not involving
insolvency or bankruptcy proceedings; or (iv) there is initiated any assignment for the benefit of
creditors or any marshalling of the material assets or material liabilities of the Company or any
Company Subsidiary.

          “Maturity Date” has the meaning set forth in the preamble of this Note.

          “Prepayment Date” has the meaning set forth in Section 4 of this Note.

          “Prepayment Notice” has the meaning set forth in Section 4 of this Note.

          “Securities Purchase Agreement” has the meaning set forth in the preamble of this Note.

     (b) Terms Defined in Securities Purchase Agreement. Any capitalized term used but not
defined herein has the meaning specified in the Securities Purchase Agreement.

3

 

     (c) Usage. All definitions contained in this Note are equally applicable to the
singular and plural forms of the terms defined. The words “hereof”, “herein” and “hereunder” and
words of similar import refer to this Note as a whole and not to any particular provision of this
Note.

2. ACCRETION; PAYMENT OF PRINCIPAL.

     (a) Accretion of Principal. During the period commencing on the Issue Date and ending
on the one year anniversary of the Issue Date (the “Accretion Period”), the outstanding principal
of this Note shall accrete in value at an annual rate equal to ten percent (10.0%), compounded
monthly, and computed on the basis of a 360-day year and calculated using the actual number of days
elapsed since the Issue Date. Assuming no principal of this Note is prepaid prior to the
expiration of the Accretion Period, the outstanding principal of this Note shall accrete in
accordance with the following schedule:

	 	 	 	 	 
	March 24, 2008
	 	$	500,000.00	 
	April 24, 2008
	 	$	504,166.67	 
	May 24, 2008
	 	$	508,368.06	 
	June 24, 2008
	 	$	512,604.46	 
	July 24, 2008
	 	$	516,876.16	 
	August 24, 2008
	 	$	521,183.46	 
	September 24, 2008
	 	$	525,526.66	 
	October 24, 2008
	 	$	529,906.05	 
	November 24, 2008
	 	$	534,321.93	 
	December 24, 2008
	 	$	538,774.61	 
	January 24, 2009
	 	$	543,264.40	 
	February 24, 2009
	 	$	547,791.60	 
	March 24, 2009
	 	$	552,356.53	 

     (b) Payment on Maturity Date. The outstanding principal amount of this Note (as
accreted in accordance with Section 2(a)) plus all other amounts due hereunder (including default
interest (if any)), shall be paid in full on the Maturity Date.

     (c) Default Interest. Upon the occurrence of an Event of Default, the outstanding
principal amount of this Note (as accreted in accordance with Section 2(a)) shall accrue interest
at the Default Interest Rate, compounded monthly, until such Event of Default has been cured. Any
amount of principal that is not paid as and when due in accordance with this Note shall bear
interest at the Default Interest Rate, compounded monthly, until paid.

     (d) Payment in Cash. All payments of principal, and other amounts due hereunder
(including default interest (if any)), shall be paid in cash by wire transfer of immediately
available funds.

3. EVENTS OF DEFAULT; CHANGE OF CONTROL.

     In the event that an Event of Default or a Change of Control occurs, the Holder shall have the
right, upon written notice to the Company (an “Acceleration Notice”), to (i) accelerate the

4

 

payment of all unpaid principal (as accreted in accordance with Section 2(a)) of this Note
plus all other amounts due hereunder (including default interest (if any)), and (ii) receive from
the Company an amount equal to the product of (x) 1.10 and (y) the sum of all of the amounts
described in the preceding clause (i); and all such amounts shall be paid in same day funds on the
payment date specified in the Acceleration Notice, provided such payment date must be at least two
(2) Business Days following the date on which the Acceleration Notice is delivered to the Company.

4. OPTIONAL PREPAYMENT.

     The Company shall have the right at any time, upon not less than 30 days’ prior notice to the
Holder (a “Prepayment Notice”), to prepay all but not less than all of the unpaid principal (as
accreted in accordance with Section 2(a)) of this Note plus all other amounts due hereunder
(including default interest (if any)). In order to effectuate such prepayment, the Company shall
be obligated to pay the Holder an amount equal to the product of (x) 1.02 and (y) the sum of all of
the amounts described in the preceding sentence; and all such amounts shall be paid in same day
funds on the payment date specified in the Prepayment Notice (the “Prepayment Date”). A Prepayment
Notice shall be irrevocable; provided, however, that if the Holder delivers an Acceleration Notice
at any time prior to the Prepayment Date, then the provisions of Section 3 shall apply and control.

5. MISCELLANEOUS.

     (a) Failure to Exercise Rights not Waiver. No failure or delay on the part of the
Holder in the exercise of any power, right or privilege hereunder shall operate as a waiver
thereof, nor shall any single or partial exercise of any such power, right or privilege preclude
any other or further exercise thereof. All rights and remedies of the Holder hereunder are
cumulative and not exclusive of any rights or remedies otherwise available. In the event that the
Company does not pay any amount under this Note when such amount becomes due, the Company shall
bear all costs incurred by the Holder in collecting such amount, including without limitation
reasonable legal fees and expenses.

     (b) Notices. Any notice, demand or request required or permitted to be given by the
Company or the Holder pursuant to the terms of this Note shall be in writing and shall be deemed
delivered (i) when delivered personally or by verifiable facsimile transmission, unless such
delivery is made on a day that is not a Business Day, in which case such delivery will be deemed to
be made on the next succeeding Business Day, (ii) on the next Business Day after timely delivery to
an overnight courier and (iii) on the Business Day actually received if deposited in the U.S. mail
(certified or registered mail, return receipt requested, postage prepaid), addressed as follows:

If to the Company:

Echo Therapeutics, Inc.

10 Forge Parkway

Franklin, MA 02038

Attn: Chief Financial Officer

Tel: (508) 530-0311

Fax: (508) 553-8760

5

 

With a copy (which shall not constitute notice) to:

Drinker Biddle & Reath LLP

One Logan Square

18th & Cherry Streets

Philadelphia, PA 19103

Attn: Stephen T. Burdumy, Esq.

Tel: (215) 988-2700

Fax: (215) 988-2757

and if to the Holder, to such address for the Holder as shall appear on the signature page of the
Securities Purchase Agreement executed by the Holder, or as shall be designated by the Holder in
writing to the other parties hereto in accordance this Section 5(b).

     (c) Amendments and Waivers. No amendment to this Note may be made or given except
pursuant to a written instrument executed by the Company and by the Holder. No waiver of any
provision of this Note may be made except pursuant to a written instrument executed by the party
against whom such waiver is sought to be enforced. Any waiver given pursuant hereto shall be
effective only in the specific instance and for the specific purpose for which given.

     (d) Transfer of Note. The Holder may sell, transfer or otherwise dispose of all or
any part of this Note (including without limitation pursuant to a pledge) to any Person as long as
such sale, transfer or disposition is in compliance with applicable Governmental Requirements, and
is otherwise made in accordance with the applicable provisions of the Securities Purchase
Agreement. From and after the date of any such sale, transfer or disposition, the transferee
hereof shall be deemed to be the holder of a Note in the principal amount acquired by such
transferee, and the Company shall, as promptly as practicable, issue and deliver to such transferee
a new Note identical in all respects to this Note, in the name of such transferee, against
surrender of this Note or as otherwise specified in Section 5(e). The Company shall be entitled to
treat the original Holder as the holder of this entire Note unless and until it receives written
notice of the sale, transfer or disposition hereof.

     (e) Lost or Stolen Note. Upon receipt by the Company of evidence of the loss, theft,
destruction or mutilation of this Note, and (in the case of loss, theft or destruction) of
indemnity or security reasonably satisfactory to the Company, and upon surrender and cancellation
of the Note, if mutilated, the Company shall execute and deliver to the Holder a new Note identical
in all respects to this Note.

     (f) Governing Law. This Note shall be governed by and construed in accordance with
the laws of the State of New York applicable to contracts made and to be performed entirely within
the State of New York.

     (g) Successors and Assigns. The terms and conditions of this Note shall inure to the
benefit of and be binding upon the respective successors (whether by merger or otherwise) and
permitted

6

 

assigns of the Company and the Holder. The Company may not assign its rights or obligations
under this Note except as specifically required or permitted pursuant to the terms hereof;
provided, however, for purposes of clarity, except in connection with or in furtherance of any
migratory merger effected solely for the purpose of changing the jurisdiction of incorporation of
the Company.

     (h) Usury. This Note is subject to the express condition that at no time shall the
Company be obligated or required to pay interest hereunder at a rate which could subject the Holder
to either civil or criminal liability as a result of being in excess of the maximum interest rate
which the Company is permitted by applicable law to contract or agree to pay.  If by the terms of
this Note, the Company is at any time required or obligated to pay interest hereunder at a rate in
excess of such maximum rate, the rate of interest under this Note shall be deemed to be immediately
reduced to such maximum rate and the interest payable shall be computed at such maximum rate and
all prior interest payments in excess of such maximum rate shall be applied and shall be deemed to
have been payments in reduction of the principal balance of this Note. 

[Signature Page to Follow]

7

 

     IN WITNESS WHEREOF, the Company has caused this Note to be signed in its name by its duly
authorized officer on the date first above written.

	 	 	 	 	 
	ECHO THERAPEUTICS, INC.	 	 
	 
	 	 	 	 
	By:
	 	 	 	 
	 

	 	 	 	 
	 

	 	Patrick T. Mooney, M.D.	 	 
	 

	 	Chief Executive Officerexv10w3

 

Exhibit 10.3

THIS WARRANT (THIS “WARRANT”) AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE
SECURITIES LAW, AND MAY NOT BE OFFERED FOR SALE OR SOLD UNLESS A REGISTRATION STATEMENT UNDER SUCH
ACT AND APPLICABLE STATE SECURITIES LAWS SHALL BE EFFECTIVE WITH RESPECT THERETO, OR AN EXEMPTION
FROM REGISTRATION UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS IS AVAILABLE IN
CONNECTION WITH SUCH OFFER OR SALE. THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF
MAY NOT BE TRANSFERRED OR ASSIGNED TO ANY PERSON EXCEPT IN COMPLIANCE WITH APPLICABLE SECURITIES
LAWS.

WARRANT 

TO PURCHASE COMMON STOCK 

OF

ECHO THERAPEUTICS, INC.

			
	Issue Date: March 24, 2008
	 	Warrant No.                     

     THIS WARRANT of ECHO THERAPEUTICS, INC., a Minnesota corporation (the “Company”), certifies
that                     ., a                      company, and its successors and permitted assigns (the
“Holder”), has the right to purchase up to             
         shares (such shares, the number of which may
be adjusted hereunder, are referred to herein as the “Warrant Shares”) of the Company’s common
stock, par value $0.01 per share (the “Common Stock”). The per share purchase price payable by the
Holder for the Warrant Shares shall be $2.00 (such price, as may be adjusted hereunder, is referred
to herein as the “Exercise Price”). The Holder may exercise this Warrant at any time and from time
to time beginning on the Issue Date and ending at 5:00 p.m., New York City time, on the fifth
anniversary of the Issue Date or, if such day is not a Business Day, on the next succeeding
Business Day.

     This Warrant has been issued pursuant to a Securities Purchase and Loan Agreement, dated as of
the date hereof (the “Securities Purchase Agreement”), by and between the Company and the Holder.

 

 

     1. DEFINITIONS.

     (a) Defined Terms. The following terms shall apply to this Warrant:

          “Assumed Variable Market Price” has the meaning set forth in Section 4(d)(ii)(B) of this
Warrant.

          “Cash Exercise” and “Cashless Exercise” have the respective meanings set forth in Section 2(c)
of this Warrant.

          “Common Stock” has the meaning set forth in the preamble to this Warrant.

          “Company” has the meaning set forth in the preamble to this Warrant.

          “Convertible Securities” means any stock or securities (other than Options) of the Company
convertible into or exercisable or exchangeable for Common Stock.

          “Delivery Date” has the meaning set forth in Section 3(a) of this Warrant.

          “Determination Date” has the meaning set forth in Section 4(b) of this Warrant.

          “Dilutive Issuance” has the meaning set forth in Section 4(d)(i) of this Warrant.

          “Dispute Procedure” has the meaning set forth in Section 2(b) of this Warrant.

          “Distribution”, “Distribution Date” and Distribution Notice” have the respective meanings set
forth in Section4(b) of this Warrant.

          “Distribution Per Share Value” means, with respect to a Distribution, the aggregate fair
market value of the assets to be so distributed divided by the number of shares of Common Stock as
to which such Distribution is to be made. For purposes of this definition, the fair market value
of any distributed assets shall be the value agreed to by the Company and the Holder in good faith.
If the Company and the Holder are unable to agree on such fair market value within three Business
Days, the Company shall submit such dispute to an independent investment banking firm of national
reputation reasonably acceptable to the Holder, and shall cause such investment banking firm to
perform such determination and notify the Company and the Holder of the results of determination no
later than five Business Days from the time such dispute was submitted to it by the Company. Such
investment bank’s determination shall be deemed conclusive absent manifest error. The fees of any
such investment bank shall be borne by the party whose calculations were most at variance with
those of such investment bank.

          “DTC” has the meaning set forth in Section 3(b) of this Warrant.

          “Excluded Securities” means (i) issuances of shares of Common Stock or Options to employees,
officers, directors or consultants of the Company duly approved by a majority of the disinterested
members of the Board of Directors or a majority of the disinterested

-2-

 

members of a committee of the Board of Directors established for such purpose; (ii) issuances
of securities upon the exercise or exchange of or conversion of any securities exercisable or
exchangeable for or convertible into shares of Common Stock issued and outstanding on the Issue
Date, provided that such securities have not been amended since the Issue Date to increase the
number of such securities or to decrease the exercise, exchange or conversion price of any such
securities; (iii) securities issued at fair market value in connection with acquisitions or
strategic transactions approved by a majority of the disinterested members of the Board of
Directors, but not including a transaction with an entity whose primary business is investing in
securities or a transaction, the primary purpose of which is to raise capital; (iv) the exercise of
this Warrant or any portion hereof; (v) the issuance of securities at fair market value pursuant to
any equipment financing or commercial business arrangement with one or more banks or similar
financial or lending institutions approved by the Board of Directors to the extent such issuances
do not, in the aggregate, exceed two percent (2%) of the issued and outstanding shares of Common
Stock on the date hereof; (vi) the issuance of any shares of Common Stock or Convertible Securities
as payment of interest in connection with the Company’s 8% Senior Convertible Promissory Notes, due
February 12, 2011, in accordance with the terms of such notes as in effect as of the Execution
Date; (vii) securities issued in any transaction that is approved in writing by the Holder; and
(viii) shares of Common Stock issued in connection with any subdivision of Common Stock covered by
Section 4(a).

          “Exercise Date” has the meaning set forth in Section 2(a) of this Warrant.

          “Exercise Default” has the meaning set forth in Section 3(c) of this Warrant.

          “Exercise Notice” has the meaning set forth in Section 2(a) of this Warrant.

          “Exercise Price” has the meaning set forth in the preamble to this Warrant.

          “Holder” has the meaning set forth in the preamble to this Warrant.

          “Issue Date” means the Issue Date set forth on the front page of this Warrant.

          “Major Transaction” means the existence, occurrence or public announcement of, or entering
into an agreement contemplating, a merger, consolidation, business combination, tender offer,
exchange of shares, recapitalization, reorganization, redemption or other similar event, as a
result of which shares of Common Stock shall be changed into, or exchanged or tendered for, the
same or a different number of shares of the same or another class or classes of stock or securities
or other assets of the Company or another entity, or the Company shall sell all or substantially
all of its assets. A subdivision or combination of Common Stock that is covered by Section 4(a)
shall not constitute a “Major Transaction”.

          “Market Price” means, as of a particular date, the highest daily VWAP during the period of 20
consecutive Trading Days occurring immediately prior to (but not including) such date.

          “Options” means any rights, warrants or options to subscribe for, purchase or receive Common
Stock or Convertible Securities.

-3-

 

          “Record Date” has the meaning set forth in Section 4(b) of this Warrant.

          “Securities Purchase Agreement” has the meaning set forth in the preamble to this Warrant.

          “VWAP” means, with respect to a Trading Day, the volume weighted average price of the Common
Stock for such Trading Day on the Principal Market as reported by Bloomberg Financial Markets or,
if Bloomberg Financial Markets is not then reporting such prices, by a comparable reporting service
of national reputation selected by the Company and reasonably satisfactory to the Holder. If VWAP
cannot be calculated for the Common Stock on such Trading Day on the foregoing bases, then the
Company shall, at its sole cost and expense, submit such calculation to an independent investment
banking firm of national reputation reasonably acceptable to the Holder, and shall cause such
investment banking firm to perform such determination and notify the Company and the Holder of the
results of determination no later than five Business Days from the time such calculation was
submitted to it by the Company.

          “Warrant Shares” has the meaning set forth in the preamble to this Warrant.

     (b) Terms Defined in the Securities Purchase Agreement. Any capitalized term used but
not defined herein has the meaning specified in the Securities Purchase Agreement.

     (c) Usage. All definitions contained in this Warrant are equally applicable to the
singular and plural forms of the terms defined. The words “hereof”, “herein” and “hereunder” and
words of similar import refer to this Warrant as a whole and not to any particular provision of
this Warrant.

2. EXERCISE OF WARRANT.

     (a) Exercise Notice. In order to exercise this Warrant, the Holder shall (i) deliver
to the Company a completed exercise notice in the form attached hereto as Exhibit A (the “Exercise
Notice”) and (ii) pay the Exercise Price in accordance with Section 2(c). The Holder shall
promptly thereafter deliver this Warrant to the Company for cancellation (and replacement with a
new Warrant if exercised in part) pursuant to Section 2(e). The Holder shall be deemed to have
exercised this Warrant on the date (the “Exercise Date”) on which the applicable Exercise Notice
was deemed delivered under Section 5(b).

     (b) Disputes. In the case of a dispute as to the calculation of the Exercise Price or
the number of Warrant Shares issuable hereunder (including, without limitation, the calculation of
any adjustment pursuant to Section 4), the Company shall promptly issue to the Holder the number of
Warrant Shares that are not disputed and shall submit the disputed calculations to a certified
public accounting firm of national recognition (other than the Company’s independent accountants
and reasonably acceptable to the Holder) within three Business Days following the applicable
Exercise Date. The Company shall use its best efforts to cause such accountant to calculate the
Exercise Price and/or the number of Warrant Shares issuable hereunder and to

-4-

 

notify the Company and the Holder of the results in writing no later than three Business Days
following the day on which such accountant received the disputed calculations (the “Dispute
Procedure”). Such accountant’s calculation shall be deemed conclusive absent manifest error. The
fees of any such accountant shall be borne by the party whose calculations were most at variance
with those of such accountant.

     (c) Payment of Exercise Price; Cashless Exercise. The Holder may pay the Exercise
Price in either of the following forms or, at the election of Holder, a combination thereof:

          (i) through a cash exercise (a “Cash Exercise”) by delivering immediately available funds, or

          (ii) if an effective Registration Statement is not available for the resale of all of the
Warrant Shares issuable hereunder at the time an Exercise Notice is delivered to the Company,
through a cashless exercise (a “Cashless Exercise”), as hereinafter provided. The Holder may
effect a Cashless Exercise by surrendering this Warrant to the Company and noting on the Exercise
Notice that the Holder wishes to effect a Cashless Exercise, upon which the Company shall issue to
the Holder the number of Warrant Shares determined as follows:

	 	 	 	 	 	 	 
	 

	 	where:
	 	A =
	 	the number of Warrant Shares to be issued to
the Holder in such Cashless Exercise.
	 
	 	 	 	 	 	 
	 

	 	 	 	B =
	 	the number of Warrant Shares subject to such
Cashless Exercise.
	 
	 	 	 	 	 	 
	 

	 	 	 	C =
	 	the Market Price as of the Exercise Date.
	 
	 	 	 	 	 	 
	 

	 	 	 	D =
	 	the Exercise Price as of the Exercise Date.

For purposes of Rule 144, it is intended and acknowledged that the Warrant Shares issued in a
Cashless Exercise transaction shall be deemed to have been acquired by the Holder, and the holding
period for the Warrant Shares required by Rule 144 shall be deemed to have been commenced, on the
Issue Date.

     (d) Holder of Record. The Holder shall, for all purposes, be deemed to have become
the holder of record of the Warrant Shares specified in an Exercise Notice on the Exercise Date
specified therein, irrespective of the date of delivery of such Warrant Shares. Except as
specifically provided herein, nothing in this Warrant shall be construed as conferring upon the
Holder hereof any rights as a stockholder of the Company prior to the Exercise Date.

     (e) Cancellation or Replacement of Warrant. This Warrant shall be canceled upon its
exercise and, if this Warrant is exercised in part, the Company shall, at the time that it delivers
Warrant Shares to the Holder pursuant to such exercise as provided herein, issue a new warrant,

-5-

 

and deliver to the Holder a certificate representing such new warrant, with terms identical in all
respects to this Warrant (except that such new warrant shall be exercisable into the number of
shares of Common Stock with respect to which this Warrant shall remain unexercised); provided,
however, that the Holder shall be entitled to exercise all or any portion of such new warrant at
any time following the time at which this Warrant is exercised, regardless of whether the Company
has actually issued such new warrant or delivered to the Holder a certificate therefor.

     (f) Exercise Limitation. Notwithstanding any provision herein to the contrary, the
Holder shall not be permitted to exercise this Warrant if, upon such exercise, the number of shares
of Common Stock beneficially owned by the Holder (other than shares which may be deemed
beneficially owned except for being subject to a limitation on exercise or exercise analogous to
the limitation contained in this Section 2(f)), would exceed 9.9% of the number of shares of Common
Stock then issued and outstanding, it being the intent of the Company and the Holder that the
Holder not be deemed at any time to have the power to vote or dispose of greater than 9.9% of the
number of shares of Common Stock issued and outstanding at any time. Nothing contained herein shall
be deemed to restrict the right of the Holder to exercise this Warrant at such time as such
exercise will not violate the provisions of this Section 2(f). As used herein, beneficial
ownership shall be determined in accordance with Section 13(d) of the Exchange Act. The holders of
Common Stock are to be deemed third-party beneficiaries of the limitation imposed hereby and,
accordingly, this Section 2(f) may not be amended without the consent of the holders of a majority
of the shares of Common Stock then outstanding; provided, however, that the Holder shall have the
right, upon 60 days’ prior written notice to the Company, to waive the provisions of this Section
2(f) without obtaining such consent.

     3. DELIVERY OF WARRANT SHARES.

          (a) Delivery Date. With respect to a Cash Exercise, the Company shall deliver the
Warrant Shares subject to such exercise no later than the close of business on the later to occur
of (i) the third Business Day following the Exercise Date set forth in such Exercise Notice and
(ii) the date on which the Company has received payment of the applicable Exercise Price. With
respect to a Cashless Exercise, the Company shall deliver the Warrant Shares subject to such
exercise no later than the close of business on the third Business Day following the Exercise Date
set forth in such Exercise Notice. With respect to Warrant Shares that are the subject of a
Dispute Procedure, the Company shall deliver the Warrant Shares required to be delivered (if any)
no later than the close of business on the third Business Day following the resolution of such
dispute pursuant to Section 2(b). Each of the delivery dates specified in this Section 3(a) is
referred to herein as a “Delivery Date”.

          (b) Method of Delivery. The Company or its designated transfer agent (the “Transfer
Agent”) shall effect delivery of Warrant Shares in accordance with the method of delivery selected
by the Holder in its Exercise Notice. If the Holder selects delivery through the Depository Trust
Company (“DTC”), then the Company shall issue and deliver such shares to the Holder’s DTC account
specified on such Exercise Notice via the Deposit Withdrawal Agent Commission System. In the event
that any Warrant Shares are restricted and may not be delivered in accordance with the preceding
sentence, or if the Holder as selected delivery of physical certificates in its Exercise Notice,
the Company shall issue and deliver (by hand or overnight courier

-6-

 

only) to the Holder or its nominee physical certificates representing such Warrant Shares, and such
certificates shall not contain any restrictive legend unless required under the Securities Purchase
Agreement.

          (c) Failure to Deliver. In the event that the Company (i) fails for any reason (other
than as a result of the Holder’s failure, in the case of a Cash Exercise, to pay the applicable
Exercise Price for the Warrant Shares) to deliver Warrant Shares to the Holder as and when required
under Sections 3(a) and 3(b), or (ii) fails to remove any restrictive legend from any outstanding
Warrant Shares at the request of the Holder as and when required under the Securities Purchase
Agreement (either such failure being referred to herein as an “Exercise Default”), the Holder shall
have the right to receive from the Company an amount equal to (x) (N/365) multiplied by (y) the
aggregate Market Price of the Warrant Shares (calculated as of the date on which the applicable
Exercise Notice was delivered) which are the subject of such Exercise Default multiplied by (z) the
lower of eighteen percent (18%) and the maximum rate permitted by applicable Governmental
Requirements, where “N” equals the number of days elapsed between (1) the date on which such
Exercise Default first occurred and (2) the date on which such Exercise Default is finally cured.
Amounts payable under the preceding sentence shall be paid to the Holder in immediately available
funds on or before the second Business Day following written notice from the Holder to the Company
specifying the amount owed to it by the Company. In the event that shares of Common Stock are
purchased by or on behalf of the Holder in order to make delivery on a sale effected in
anticipation of receiving Warrant Shares upon an exercise, the Holder shall have the right to
receive from the Company, in addition to the foregoing amounts, (i) the aggregate amount paid by or
on behalf of the Holder for such shares of Common Stock minus (ii) the aggregate amount of the net
proceeds, if any, received by the Holder from the sale of the Warrant Shares if and when delivered
to the Holder. In addition to the foregoing rights arising upon an Exercise Default, the Holder
shall have the right to pursue all other remedies available to it at law or in equity (including,
without limitation, a decree of specific performance and/or injunctive relief).

     4. ANTI-DILUTION ADJUSTMENTS; DISTRIBUTIONS; OTHER EVENTS.

     The Exercise Price and the number of Warrant Shares issuable hereunder shall be subject to
adjustment from time to time as provided in this Section 4.

          (a) Subdivision or Combination of Common Stock. If the Company, at any time after the
Issue Date, subdivides (by any stock split, stock dividend or similar transaction) its shares of
Common Stock into a greater number of shares, then after the date of record for effecting such
subdivision, the Exercise Price in effect immediately prior to such subdivision will be
proportionately reduced. If the Company, at any time after the Issue Date, combines (by reverse
stock split or similar transaction) its shares of Common Stock into a smaller number of shares,
then, after the date of record for effecting such combination, the Exercise Price in effect
immediately prior to such combination will be proportionally increased.

          (b) Distributions. If, at any time after the Issue Date, the Company declares or
makes any distribution of cash or any other assets (or rights to acquire such assets) to holders of
Common Stock, including without limitation any dividend or distribution to the Company’s
stockholders in shares (or rights to acquire shares) of capital stock of a subsidiary (a

-7-

 

     “Distribution”), the Company shall deliver written notice of such Distribution (a
“Distribution Notice”) to the Holder at least fifteen (15) days prior to the earlier to occur of
(i) the record date for determining stockholders entitled to such Distribution (the “Record Date”)
and (ii) the date on which such Distribution is made (the “Distribution Date”) (the earlier of such
dates being referred to as the “Determination Date”). Upon receipt of the Distribution Notice, the
Holder shall promptly (but in no event later than three Business Days) notify the Company whether
it has elected (A) to receive the same amount and type of assets (including, without limitation,
cash) being distributed as though the Holder were, on the Determination Date, a holder of a number
of shares of Common Stock into which this Warrant is exercisable as of such Determination Date
(such number of shares to be determined without giving effect to any limitations on such exercise)
or (B) upon any exercise of this Warrant on or after the Distribution Date, to reduce the Exercise
Price in effect on the Business Day immediately preceding the Record Date (such date being deemed
the Exercise Date for purposes hereof) by an amount equal to the Distribution Per Share Value.
Upon receipt of such election notice from the Holder, the Company shall timely effectuate the
transaction or adjustment contemplated in the foregoing clauses (A) or (B), as applicable. If the
Holder does not notify the Company of its election pursuant to the preceding sentence on or prior
to the Determination Date, the Holder shall be deemed to have elected clause (A) of the preceding
sentence.

          (c) Convertible Securities; Options. If, at any time after the Issue Date, the
Company issues Convertible Securities or Options to the record holders of the Common Stock, whether
or not such Convertible Securities or Options are immediately convertible, exercisable or
exchangeable, then the Holders shall be entitled, upon any exercise of this Warrant on or after the
date of record for determining stockholders entitled to receive such Convertible Securities or
Options (or if no such record is taken, the date on which such Convertible Securities or Options
are issued), to receive the aggregate number of Convertible Securities or Options which the Holder
would have received with respect to the shares of Common Stock issuable upon such exercise (without
giving effect to any limitations on such exercise contained in this Warrant) had the Holder been
the holder of such shares of Common Stock on the record date for the determination of stockholders
entitled to receive such Convertible Securities or Options (or if no such record is taken, the date
on which such Convertible Securities or Options were issued).

          (d) Dilutive Issuances.

               (i) Adjustment upon Dilutive Issuance. If, at any time after the Issue Date, the
Company issues or sells, or in accordance with Section 4(d)(ii) is deemed to have issued or sold,
any shares of Common Stock for no consideration or for a consideration per share less than the
Exercise Price in effect on the date of such issuance or sale (or deemed issuance or sale) (a
“Dilutive Issuance”), then the Exercise Price shall be adjusted so as to equal an amount determined
by multiplying such Exercise Price by the following fraction:

               where:

-8-

 

	 	N0 =	 	 the number of shares of Common Stock outstanding
immediately prior to the issuance, sale or deemed issuance or
sale of such additional shares of Common Stock in such Dilutive
Issuance (without taking into account any shares of Common Stock
issuable upon conversion, exchange or exercise of any
outstanding Options or Convertible Securities (other than the
Warrant));
	 
	 	N1 =	 	 the number of shares of Common Stock which the
aggregate consideration, if any, received or receivable by the
Company for the total number of such additional shares of Common
Stock so issued, sold or deemed issued or sold in such Dilutive
Issuance (which, in the case of a deemed issuance or sale, shall
be calculated in accordance with Section 4(d)(ii)) would
purchase at the Exercise Price in effect immediately prior to
such Dilutive Issuance; and
	 
	 	N2 =	 	 the number of Common Stock issued, sold or deemed
issued or sold in such Dilutive Issuance.

Notwithstanding the foregoing, no adjustments to the Exercise Price shall be made pursuant to this
Section 4(d)(i) for any issuance of Excluded Securities.

          (ii) Effect on Exercise Price of Certain Events. For purposes of determining the
adjusted Exercise Price under Section 4(d)(i), the following will be applicable:

               (A) Issuance of Options. If the Company issues or sells any Options, whether or not
immediately exercisable, and the price per share for which Common Stock is issuable upon the
exercise of such Options (and the price of any conversion of Convertible Securities, if applicable)
is less than the Exercise Price in effect on the date of issuance or sale of such Options (such
date being deemed the Exercise Date for purposes hereof), then the maximum total number of shares
of Common Stock issuable upon the exercise of all such Options (assuming full conversion, exercise
or exchange of Convertible Securities, if applicable) shall, as of the date of the issuance or sale
of such Options, be deemed to be outstanding and to have been issued and sold by the Company for
such price per share. For purposes of the preceding sentence, the “price per share for which Common
Stock is issuable upon the exercise of such Options” shall be determined by dividing (x) the total
amount, if any, received or receivable by the Company as consideration for the issuance or sale of
all such Options, plus the minimum aggregate amount of additional consideration, if any, payable to
the Company upon the exercise of all such Options, plus, in the case of Convertible Securities
issuable upon the exercise of such Options, the minimum aggregate amount of additional
consideration payable upon the conversion, exercise or exchange thereof (determined in accordance
with the calculation method set forth in Section 4(d)(ii)(B) below) at the time such Convertible
Securities first become convertible, exercisable or exchangeable, by (y) the maximum total number
of shares of Common Stock issuable upon the exercise of all such Options (assuming full conversion,
exercise or exchange of Convertible Securities, if applicable). No further adjustment to the
Exercise Price shall be made upon the actual issuance of such Common Stock upon the

-9-

 

exercise of such Options or upon the conversion, exercise or exchange of Convertible
Securities issuable upon exercise of such Options. To the extent that shares of Common Stock or
Convertible Securities are not delivered pursuant to such Options, upon the expiration or
termination of such Options, the Exercise Price shall be readjusted to the Exercise Price that
would then be in effect had the adjustments made upon the issuance of such Options been made on the
basis of delivery of only the number of shares of Common Stock actually delivered.

               (B) Issuance Of Convertible Securities. If the Company issues or sells any
Convertible Securities, whether or not immediately convertible, exercisable or exchangeable, and
the price per share for which Common Stock is issuable upon such conversion, exercise or exchange
is less than the Exercise Price in effect on the date of issuance or sale of such Convertible
Securities (such date being deemed the Exercise Date for purposes hereof), then the maximum total
number of shares of Common Stock issuable upon the conversion, exercise or exchange of all such
Convertible Securities shall, as of the date of the issuance or sale of such Convertible
Securities, be deemed to be outstanding and to have been issued and sold by the Company for such
price per share. If the Convertible Securities so issued or sold do not have a fluctuating
conversion or exercise price or exchange ratio, then for the purposes of the immediately preceding
sentence, the “price per share for which Common Stock is issuable upon such conversion, exercise or
exchange” shall be determined by dividing (A) the total amount, if any, received or receivable by
the Company as consideration for the issuance or sale of all such Convertible Securities, plus the
minimum aggregate amount of additional consideration, if any, payable to the Company upon the
conversion, exercise or exchange thereof (determined in accordance with the calculation method set
forth in this Section 4(d)(ii)(B)) at the time such Convertible Securities first become
convertible, exercisable or exchangeable, by (B) the maximum total number of shares of Common Stock
issuable upon the exercise, conversion or exchange of all such Convertible Securities. If the
Convertible Securities so issued or sold have a fluctuating conversion or exercise price or
exchange ratio (a “Variable Rate Security”), then for purposes of the first sentence of this
Section 4(d)(ii)(B), the “price per share for which Common Stock is issuable upon such conversion,
exercise or exchange” shall be deemed to be the lowest price per share which would be applicable
(assuming all holding period and other conditions to any discounts contained in such Variable Rate
Security have been satisfied) if the conversion price of such Variable Rate Security on the date of
issuance or sale thereof were equal to the actual conversion price on such date (or such higher
minimum conversion price if such Variable Rate Security is subject to a minimum conversion price)
(the “Assumed Variable Market Price”), and, further, if the conversion price of such Variable Rate
Security at any time or times thereafter is less than or equal to the Assumed Variable Market Price
last used for making any adjustment under this Section 4(d) with respect to any Variable Rate
Security, the Exercise Price in effect at such time shall be readjusted to equal the Exercise Price
which would have resulted if the Assumed Variable Market Price at the time of issuance of the
Variable Rate Security had been equal to the actual conversion price of such Variable Rate Security
existing at the time of the adjustment required by this sentence; provided, however, that if the
conversion or exercise price or exchange ratio of a Convertible Security may fluctuate solely as a
result of provisions designed to protect against dilution, such Convertible Security shall not be
deemed to be a Variable Rate Security. No further adjustment to the Exercise Price shall be made
upon the actual issuance of such Common Stock upon conversion, exercise or exchange of such
Convertible Securities.

-10-

 

               (C) Change In Option Price Or Conversion Rate. If there is a change at any time in
(x) the amount of additional consideration payable to the Company upon the exercise of any Options;
(y) the amount of additional consideration, if any, payable to the Company upon the conversion,
exercise or exchange of any Convertible Securities; or (z) the rate at which any Convertible
Securities are convertible into or exercisable or exchangeable for Common Stock (in each such case,
other than under or by reason of provisions designed to protect against dilution), the Exercise
Price in effect at the time of such change shall be readjusted to the Exercise Price which would
have been in effect at such time had such Options or Convertible Securities still outstanding
provided for such changed additional consideration or changed conversion, exercise or exchange
rate, as the case may be, at the time initially issued or sold.

               (D) Calculation Of Consideration Received. If any Common Stock, Options or
Convertible Securities are issued or sold for cash, the consideration received therefor will be the
amount received by the Company therefor. In case any Common Stock, Options or Convertible
Securities are issued or sold for a consideration part or all of which shall be other than cash,
including in the case of a strategic or similar arrangement in which the other entity will provide
services to the Company, purchase services from the Company or otherwise provide intangible
consideration to the Company, the amount of the consideration other than cash received by the
Company (including the net present value of the consideration expected by the Company for the
provided or purchased services) shall be the fair market value of such consideration. In case any
Common Stock, Options or Convertible Securities are issued in connection with any merger or
consolidation in which the Company is the surviving corporation, the amount of consideration
therefor will be deemed to be the fair market value of such portion of the net assets and business
of the non-surviving corporation as is attributable to such Common Stock, Options or Convertible
Securities, as the case may be. A majority of the independent members of the Company’s Board of
Directors shall calculate reasonably and in good faith, using standard commercial valuation methods
appropriate for valuing such assets, the fair market value of any consideration.

     (e) Major Transactions. If, at any time after the Issue Date, any Major Transaction
shall occur, then the Holder shall thereafter have the right to either (i) require the Company to
repurchase this Warrant for cash in an amount equal to the value of this Warrant calculated
pursuant to the Black-Scholes pricing model (using an expected volatility equal to the 100 day
volatility obtained from the hvt function on Bloomberg (provided that if such function yields a
volatility that is (x) less than 50%, the expected volatility shall be equal to 50%, or (y) greater
than 80%, the expected volatility shall be equal to 80%) or (ii) exercise this Warrant in whole or
in part at any time prior to, on or after the record date for the receipt of the consideration
payable to the holders of Common Stock and shall be entitled to receive, in lieu of the shares of
Common Stock otherwise issuable upon exercise of this Warrant, such shares of stock, securities
and/or other assets as would have been issued or payable upon such Major Transaction with respect
to or in exchange for the number of shares of Common Stock which would have been issuable upon
exercise of this Warrant had such Major Transaction not taken place (without giving effect to any
limitations on such exercise contained in this Warrant). The Company shall not effect any Major
Transaction unless (1) subsequent to the public disclosure by the Company of such Major
Transaction, the Holder has been given written notice of such transaction by the earlier of (A) the
date that is 30 days (61 days if, without giving effect to the limitation on exercise contained in

-11-

 

Section 2(f), the Holder would beneficially own more than 9.9% of the Common Stock then
outstanding) prior to the date on which such transaction is consummated, and (B) the date that is
fifteen (15) days prior to the record date for the determination of the Company’s stockholders
entitled to vote with respect to such transaction, and (2) the resulting successor or acquiring
entity (if not the Company) assumes by written instrument (in form and substance reasonably
satisfactory to the Holder) the obligations of the Company under this Warrant, with such
adjustments to the Exercise Price and the securities covered hereby as may be necessary in order to
preserve the economic benefits of this Warrant to the Holder. The above provisions shall apply
regardless of whether or not there would have been a sufficient number of shares of Common Stock
authorized and available for issuance upon exercise of this Warrant as of the date of such
transaction, and shall similarly apply to successive Major Transactions. For purposes of clarity, a
migratory merger effected solely for the purpose of changing the jurisdiction of incorporation of
the Company shall not itself give rise to the repurchase rights, the Black-Scholes rights nor the
notification obligations of the Company described in this Section 4(e).

          (f) Securities or Assets Other Than Common Stock. In the event that at any time, as a
result of an adjustment made pursuant to this Section 4, the Holder of this Warrant shall, upon
exercise of this Warrant, become entitled to receive securities or assets other than Common Stock;
then, wherever appropriate, all references herein to shares of Common Stock shall be deemed to
refer to and include such other securities and assets, and thereafter the number of such other
securities or assets shall be subject to adjustment from time to time in a manner and upon terms as
nearly equivalent as practicable to the provisions of this Section 4.

          (g) Adjustments to Warrant Coverage. Any adjustment made herein that results in an
increase or decrease in the Exercise Price shall also effect a proportional decrease or increase,
respectively, in the number of Warrant Shares into which this Warrant is exercisable so that the
aggregate Exercise Price that the Holder was required to pay in order to exercise this Warrant in
full immediately before such adjustment is the same as the aggregate Exercise Price that the Holder
is required to pay in order to exercise this Warrant in full immediately after such adjustment.

          (h) Notice Of Adjustments. Upon the occurrence of each adjustment or readjustment of
the Exercise Price pursuant to this Section 4 resulting in a change in the Exercise Price by more
than one percent (1%), or any change in the number or type of stock, securities and/or other
property issuable upon exercise of this Warrant, the Company, at its expense, shall promptly
compute such adjustment, readjustment or change and prepare and furnish to the Holder a certificate
setting forth such adjustment, readjustment or change and showing in detail the facts upon which
such adjustment, readjustment or change is based. The Company shall, upon the written request at
any time of the Holder, furnish to the Holder a like certificate setting forth (i) such adjustment,
readjustment or change, (ii) the Exercise Price at the time in effect and (iii) the number of
shares of Common Stock and the amount, if any, of other securities or property which at the time
would be received upon exercise of this Warrant.

     5. MISCELLANEOUS.

          (a) Failure to Exercise Rights not Waiver. No failure or delay on the part of the
Holder in the exercise of any power, right or privilege hereunder shall operate as a waiver

-12-

 

thereof, nor shall any single or partial exercise of any such power, right or privilege
preclude any other or further exercise thereof. All rights and remedies of the Holder hereunder are
cumulative and not exclusive of any rights or remedies otherwise available. In the event that the
Company breaches any of its obligations hereunder to issue Warrant Shares or pay any amounts as and
when due, the Company shall bear all costs incurred by the Holder in collecting such amount,
including without limitation reasonable legal fees and expenses.

          (b) Notices. Any notice, demand or request required or permitted to be given by the
Company or the Holder pursuant to the terms of this Warrant shall be in writing and shall be deemed
delivered (i) when delivered personally, against written receipt therefor, or by verifiable
facsimile transmission, unless such delivery is made on a day that is not a Business Day, in which
case such delivery will be deemed to be made on the next succeeding Business Day, (ii) on the next
Business Day after timely delivery to a nationally recognized overnight courier and (iii) on the
Business Day actually received if deposited in the U.S. mail (certified or registered mail, return
receipt requested, postage prepaid), addressed as follows:

If to the Company:

Echo Therapeutics, Inc.

10 Forge Parkway

Franklin, MA 02038

Attn: Chief Financial Officer

Tel: (508) 530-0311

Fax: (508) 553-8760

With a copy (which shall not constitute notice) to:

Drinker Biddle & Reath LLP

One Logan Square

18th & Cherry Streets

Philadelphia, PA 19103

Attn: Stephen T. Burdumy, Esq.

Tel: (215) 988-2700

Fax: (215) 988-2757

If to the Holder:

                                                            

                                                            

                                                            

; or as shall otherwise be designated by such party in writing to the other parties hereto in

-13-

 

accordance this Section 5(b).

     (c) Amendments and Waivers. No amendment to this Warrant may be made or given except
pursuant to a written instrument executed by the Company and by the Holder. No waiver of any
provision of this Warrant may be made except pursuant to a written instrument executed by the party
against whom such waiver is sought to be enforced. Any waiver given pursuant hereto shall be
effective only in the specific instance and for the specific purpose for which given.

     (d) Transfer of Warrant. The Holder may sell, transfer or otherwise dispose of all or
any part of this Warrant (including without limitation pursuant to a pledge) to any Person as long
as such sale, transfer or disposition is the subject of an effective registration statement under
the Securities Act and applicable state securities laws, or is exempt from registration thereunder,
and is otherwise made in accordance with the applicable provisions of the Securities Purchase
Agreement. From and after the date of any such sale, transfer or disposition, the transferee
hereof shall be deemed to be the holder of the portion of this Warrant acquired by such transferee,
and the Company shall, as promptly as practicable (but in no event later than three Business Days
from the date it receives notice thereof), issue and deliver to such transferee a new Warrant
identical in all respects to this Warrant, in the name of such transferee. The Company shall be
entitled to treat the original Holder as the holder of this entire Warrant unless and until it
receives written notice of the sale, transfer or disposition hereof.

     (e) Lost or Stolen Warrant. Upon receipt by the Company of evidence of the loss,
theft, destruction or mutilation of this Warrant, and (in the case of loss, theft or destruction)
of indemnity or security reasonably satisfactory to the Company, and upon surrender and
cancellation of this Warrant, if mutilated, the Company shall execute and deliver to the Holder a
new Warrant identical in all respects to this Warrant.

     (f) Governing Law. This Warrant shall be governed by and construed in accordance with
the laws of the State of New York applicable to contracts made and to be performed entirely within
the State of New York.

     (g) Successors and Assigns. The terms and conditions of this Warrant shall inure to
the benefit of and be binding upon the respective successors (whether by merger or otherwise) and
permitted assigns of the Company and the Holder. The Company may not assign its rights or
obligations under this Warrant except as specifically required or permitted pursuant to the terms
hereof; provided, however, for purposes of clarity, except in connection with or in furtherance of
any migratory merger effected solely for the purpose of changing the jurisdiction of incorporation
of the Company.

[Signature Page to Follow]

-14-

 

     IN WITNESS WHEREOF, the Company has duly executed and delivered this Warrant as of the Issue
Date.

	 	 	 	 	 
	 	ECHO THERAPEUTICS, INC.

 	 
	 	By:  	 	 
	 	 	Patrick T. Mooney, M.D. 	 
	 	 	Chief Executive Officer 	 

 

 

	 	 	 	 	 

EXHIBIT A to WARRANT

EXERCISE NOTICE

     THIS EXERCISE NOTICE is being delivered by the undersigned to exercise the Warrant No.                     ,
dated March 24, 2008 (the “Warrant”), issued by ECHO THERAPEUTICS, INC., a Minnesota corporation
(the “Company”), to the undersigned holder of the Warrant (the “Holder”).

	 	1.	 	The Holder hereby irrevocably exercises the Warrant to purchase                      shares
of the Company’s Common Stock, par value $0.01 per share (the “Warrant Shares”).
	 
	 	2.	 	The Exercise Price (as defined in the Warrant) as of the date of this Exercise
Notice is $                    .
	 
	 	3.	 	The Holder intends that payment of the Exercise Price be made as:
	 
	 	 	 	                     a Cash Exercise with respect to                      Warrant Shares; and/or
	 
	 	 	 	                     a Cashless Exercise with respect to                      Warrant Shares.
	 
	 	4.	 	If the Warrant Shares are to be issued to a nominee of the Holder, the name of
such nominee is                     .

Date:       
                    
      ,  20           

                                                            

Name of Holder

	 	 	 	 	 
	By:
	 	 	 	 
	 

	 	 

Name:
	 	 
	 

	 	Title:	 	 

Holder Requests Delivery to be made: (check one)

By Delivery of Physical Certificates to the Following Address:

                                                            

                                                            

                                                            

Through Depository Trust Corporation (Account                     )

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}]]